Michael Sangmin Lee

465 total citations
31 papers, 362 citations indexed

About

Michael Sangmin Lee is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael Sangmin Lee has authored 31 papers receiving a total of 362 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 16 papers in Cancer Research and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael Sangmin Lee's work include Colorectal Cancer Treatments and Studies (18 papers), Cancer Genomics and Diagnostics (14 papers) and Genetic factors in colorectal cancer (7 papers). Michael Sangmin Lee is often cited by papers focused on Colorectal Cancer Treatments and Studies (18 papers), Cancer Genomics and Diagnostics (14 papers) and Genetic factors in colorectal cancer (7 papers). Michael Sangmin Lee collaborates with scholars based in United States, South Korea and Netherlands. Michael Sangmin Lee's co-authors include Baek‐Yeol Ryoo, Kyung-Hun Lee, Michael J. Overman, Sairy Hernandez, Stacey Stein, William Grossman, Michael J. Pishvaian, Antonia Kwan, Koho Iizuka and Bo Liu and has published in prestigious journals such as Journal of Clinical Oncology and Clinical Colorectal Cancer.

In The Last Decade

Michael Sangmin Lee

28 papers receiving 358 citations

Peers

Countries citing papers authored by Michael Sangmin Lee

Since Specialization

Citations

This map shows the geographic impact of Michael Sangmin Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Sangmin Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Sangmin Lee more than expected).

Fields of papers citing papers by Michael Sangmin Lee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Sangmin Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Sangmin Lee. The network helps show where Michael Sangmin Lee may publish in the future.

Co-authorship network of co-authors of Michael Sangmin Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Sangmin Lee. A scholar is included among the top collaborators of Michael Sangmin Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Sangmin Lee. Michael Sangmin Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I/II trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAF ^V600E metastatic colorectal cancer following progression on prior BRAF+EGFR targeted therapies. 2025 ·Journal of Clinical Oncology ·(unknown), (unknown), Jason Willis, Arvind Dasari, (unknown), (unknown), Ryan Huey, Bryan K. Kee, Michael Sangmin Lee, Christine M. Parseghian, Maria Pia Morelli, John Paul Shen, (unknown), Van K. Morris	0
2	Clinical characterization and therapeutic outcomes of patients (pts) with colorectal cancer (CRC) harboring somatic BRCA1/2 mutations. 2024 ·Journal of Clinical Oncology ·Deepak Bhamidipati, (unknown), Ecaterina E. Dumbrava, Siqing Fu, David S. Hong, Daniel D. Karp, Aung Naing, Shubham Pant, Sarina A. Piha‐Paul, Jordi Rodón, Apostolia M. Tsimberidou, Amber M. Johnson, Michael Sangmin Lee, Arvind Dasari, Kanwal Raghav, Van K. Morris, Michael J. Overman, Scott Kopetz, Funda Meric‐Bernstam, Timothy A. Yap	0
3	Frequency and oncologic outcomes of KRAS mutations in circulating tumor DNA of patients with pancreatic ductal adenocarcinoma. 2024 ·Journal of Clinical Oncology ·(unknown), Mark W. Hurd, Abdelrahman Yousef, Rebecca A. Snyder, Mark Knafl, (unknown), Ray Chacko, Jennifer Peterson, Brandon G. Smaglo, Robert A. Wolff, Shubham Pant, Michael Sangmin Lee, Michael J. Overman, Ching‐Wei D. Tzeng, Matthew H. G. Katz, Huamin Wang, Anirban Maitra, Ethan B. Ludmir, John Paul Shen, Dan Zhao	2
4	Addition of metastasis-directed therapy to standard-of-care systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): Results of a multicenter, randomized phase II trial. 2024 ·Journal of Clinical Oncology ·Ethan B. Ludmir, Alexander D. Sherry, Bryan Fellman, Suyu Liu, Tharakeswara Bathala, Cara Haymaker, (unknown), Emma B. Holliday, Grace L. Smith, Michael Sangmin Lee, Dan Zhao, Brandon G. Smaglo, Cullen M. Taniguchi, Eugene J. Koay, Matthew H. G. Katz, Robert A. Wolff, Prajnan Das, Shubham Pant, Albert C. Koong, Chad Tang	6
5	Preliminary results from ERAS-007 plus palbociclib (palbo) in patients (pts) with KRAS/NRAS mutant (m) colorectal cancer (CRC) or KRASm pancreatic ductal adenocarcinoma (PDAC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers). 2023 ·Journal of Clinical Oncology ·Susanna V. Ulahannan, David R. Spigel, Michael Sangmin Lee, Marwan Fakih, Patrick Grierson, Eric S. Christenson, E. Gabriela Chiorean, Darryl Outlaw, Gazala Khan, Chloé E. Atreya, Aparna R. Parikh, Farshid Dayyani, Alexander I. Spira, Scott Kopetz, Andrea J. Bullock, Zhengrong Li, (unknown), Hina Patel, Saswati Hazra, John H. Strickler	1
6	Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers). 2023 ·Journal of Clinical Oncology ·Michael Sangmin Lee, Aparna R. Parikh, David R. Spigel, Farshid Dayyani, Alexander I. Spira, Chloé E. Atreya, Susanna V. Ulahannan, John H. Strickler, Marwan Fakih, Patrick Grierson, Eric S. Christenson, Darryl Outlaw, Gazala Khan, Scott Kopetz, Andrea J. Bullock, Zhengrong Li, Xiaoying Chen, Hina Patel, Saswati Hazra, E. Gabriela Chiorean	2
7	Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program. 2023 ·Journal of Clinical Oncology ·Arvind Dasari, (unknown), Kristin Alfaro-Munoz, Ryan Huey, Benny Johnson, Michael Sangmin Lee, Maria Pia Morelli, Van K. Morris, Michael J. Overman, Christine M. Parseghian, Kanwal Raghav, John Paul Shen, Jason Willis, Timothy E. Newhook, Abhineet Uppal, Y. Nancy You, Tsuyoshi Konishi, George J. Chang, Scott Kopetz, Robert A. Wolff, (unknown)	8
8	Prognostic role of systemic inflammatory markers in patients with metastatic MSI-h/dMMR colorectal cancer receiving immunotherapy. 2022 ·Journal of Clinical Oncology ·Deepak Bhamidipati, Kanwal Raghav, Van K. Morris, Scott Kopetz, Bryan K. Kee, Benny Johnson, Jason Willis, (unknown), Maria Pia Morelli, Christine M. Parseghian, Michael Sangmin Lee, (unknown), John Paul Shen, Kaysia Ludford, Michael J. Overman	2
9	Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors. 2022 ·Journal of Clinical Oncology ·Robin Kate Kelley, Eric Van Cutsem, Michael Sangmin Lee, Ido Wolf, Marwan Fakih, Judith de Vos‐Geelen, Valerie Lee, Arndt Vogel, (unknown), (unknown), Girish S. Naik, Eileen M. O’Reilly	1
10	Phase II single-arm study of palbociclib and cetuximab rechallenge in KRAS/NRAS/BRAF wild-type (KRAS WT) metastatic colorectal cancer (mCRC) patients (pts). 2022 ·Journal of Clinical Oncology ·(unknown), Dominic T. Moore, Matthew J. Reilley, Mohamed E. Salem, Hanna K. Sanoff, (unknown), Autumn J. McRee, Michael Sangmin Lee	0
11	Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAF^V600E metastatic colorectal cancer. 2022 ·Journal of Clinical Oncology ·Van K. Morris, Christine M. Parseghian, (unknown), Benny Johnson, Kanwal Raghav, Arvind Dasari, Ryan Huey, Michael J. Overman, Jason Willis, Michael Sangmin Lee, Robert A. Wolff, Bryan K. Kee, John Paul Shen, Maria Pia Morelli, Alda L. Tam, Wai Chin Foo, Lianchun Xiao, Scott Kopetz	55
12	Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable (MSS), BRAF^V600E metastatic colorectal cancer. 2022 ·Journal of Clinical Oncology ·Van K. Morris, Christine M. Parseghian, (unknown), Benny Johnson, Kanwal Raghav, (unknown), Ryan Huey, Michael J. Overman, Jason Willis, Michael Sangmin Lee, Robert A. Wolff, Bryan K. Kee, (unknown), (unknown), (unknown), Alda L. Tam, Wai Chin Foo, Lianchun Xiao, Kyuson Yun, Scott Kopetz	12
13	Phase I study of hydroxychloroquine plus binimetinib in patients with metastatic pancreatic cancer (the HOPE trial). 2022 ·Journal of Clinical Oncology ·Rishi Surana, J. Jack Lee, Brandon G. Smaglo, Dan Zhao, Michael Sangmin Lee, Robert A. Wolff, Michael J. Overman, Jason Willis, Channing J. Der, Shubham Pant	4
14	Clinical outcomes following termination of immunotherapy due to long-term benefit in MSI-H colorectal cancer. 2022 ·Journal of Clinical Oncology ·(unknown), Bryan K. Kee, Kanwal Raghav, Benny Johnson, Scott Kopetz, Jason Willis, (unknown), (unknown), Kaysia Ludford, Christine M. Parseghian, Michael Sangmin Lee, (unknown), John Paul Shen, Michael J. Overman, Van K. Morris	2
15	Safety and efficacy of neoadjuvant pembrolizumab in mismatch repair deficient localized/locally advanced solid tumors. 2021 ·Journal of Clinical Oncology ·Kaysia Ludford, Kanwal Raghav, Mariela A. Blum Murphy, Nicole D. Fleming, Douglas A. Nelson, Michael Sangmin Lee, Brandon G. Smaglo, Y. Nancy You, (unknown), Carlos Kamiya-Matsuoka, Selvi Thirumurthi, Craig Messick, Benny Johnson, (unknown), Arvind Dasari, Jane V. Thomas, Wai Chin Foo, Wei Qiao, Scott Kopetz, Michael J. Overman	8
16	A phase Ib trial of ERK inhibition with ulixertinib combined with palbociclib in patients (Pts) with advanced solid tumors. 2021 ·Journal of Clinical Oncology ·(unknown), Brian Burgess, (unknown), (unknown), Michael Sangmin Lee, Autumn J. McRee	7
17	Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer 2020 ·Clinical Colorectal Cancer ·Shailesh Advani, Michael D. Swartz, Jonathan M. Loree, Jennifer S. Davis, (unknown), Michael S. Lam, Michael Sangmin Lee, Jan Bressler, David S. López, Carrie R. Daniel, Van K. Morris, (unknown), Bryan K. Kee, Arvind Dasari, Eduardo Vilar, Michael J. Overman, Stanley R. Hamilton, Dipen M. Maru, Dejana Braithwaite, Scott Kopetz	25
18	Association of consensus molecular subtypes (CMS) with time to progression (TTP), progression free survival (PFS), and overall survival (OS) with second-line FOLFIRI ± regorafenib in metastatic colorectal cancer (mCRC). 2019 ·Journal of Clinical Oncology ·Michael Sangmin Lee, Sara R. Selitsky, Joel S. Parker, J. Todd Auman, (unknown), (unknown), Bert H. O’Neil, Hanna K. Sanoff, Federico Innocenti	2
19	Phase Ib/II study of neoadjuvant chemoradiotherapy with CRLX101 and capecitabine for locally advanced rectal cancer. 2017 ·Journal of Clinical Oncology ·Andrew Z. Wang, Autumn J. McRee, A. William Blackstock, Bert H. O’Neil, Dominic T. Moore, Benjamin F. Calvo, Michael Sangmin Lee, Curran Murphy, (unknown), (unknown), Adrian M. Senderowicz, Joel E. Tepper, Hanna K. Sanoff, (unknown)	4
20	Association of primary (1°) site and molecular features with progression-free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) after anti-epidermal growth factor receptor (αEGFR) therapy. 2016 ·Journal of Clinical Oncology ·Michael Sangmin Lee, Shailesh Advani, Jeffrey S. Morris, Zhi-Qin Jiang, Ganiraju C. Manyam, David G. Menter, Bradley M. Broom, Cathy Eng, Michael J. Overman, Dipen M. Maru, Stanley R. Hamilton, Scott Kopetz	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact